Gland Pharma to Direct-Own US Subsidiary via Internal Restructuring
Gland Pharma Ltd 路 Outcome 路 13 Sept 2026, 9:57 pm
Gland Pharma to Direct-Own US Subsidiary via Internal Restructuring Gland Pharma Limited's board approved the 100% equity acquisition of step-down subsidiary Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd for a cash consideration of USD 5,01,208 on 13th Sep'26. The transaction transitions Gland US into a direct wholly-owned subsidiary to eliminate corporate holding layers and streamline organizational structure, with expected completion by 31st Oct'26. Gland US, engaged in pharma marketing and distribution, reported nil turnover in FY26, following USD 87,342 in FY25 and USD 4,83,808 in FY24.
Original exchange filing (PDF)
More announcements from Gland Pharma Ltd
- Schedule of Investor Meet Intimation 路 17 Nov 2026
- Allotment of 3739 Equity Shares on exercise of ESOPs 路 16 Nov 2026
- Grant of Options to Purchase Securities 路 16 Nov 2026
- Q2FY27 Earnings Call Transcript 路 12 Nov 2026
- Gland Pharma Limited has issued Corporate Guarantee on behalf of Phixen SAS, wholly owned step down subsidiary of the Company 路 12 Nov 2026
- Appointment of Mr. Xiao Le as Chief Investment Officer at Gland Pharma International Pte. Ltd, wholly owned subsidiary of Gland Pharma Limited, effective November 09, 2026 路 09 Nov 2026
- Q2FY27 Earnings Call Recording 路 07 Nov 2026
- Q2Fy27 Investors presentation 路 06 Nov 2026
